Skip to Main Content

STAT’s national biotech columnist, Adam Feuerstein, is holding a subscriber-only chat on Thursday to discuss the clinical trials, FDA approval decisions, and other events that will impact sentiment and move stocks through the end of the year.

To seed the discussion, read Adam’s scorecard of important biotech events for the fourth quarter.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!